Table 3.
Publication | Patients number | Age at LETM onset (range) years | Sex ratio | AQP4 Ab | MOG Ab | Median EDSS at nadir (range) | Chronic treatment | At least one relapse after | Follow-up duration, (range) | Median EDSS at follow-up (range) |
---|---|---|---|---|---|---|---|---|---|---|
Sepulveda et al. [13] | 23 | Median 44.5 (20–77) |
16 F 7 M |
2 | NA | 7 (3–9) | 12/23, 52% | 6/20, 30% | Median 32 months (6–54) | 2.5 (0–8) |
Kitley et al. [15] | 32 including MS, ADEM | Mean 37.74 (± 16.07) |
14 F 18 M |
0 | 6 | 8 (3–8) | NA | 31% | Median 25 months (1.9–169.4) | EDSS at recovery 3 (3–8) |
Huyn et al. [12] | 42 | Mean 43.1 (± 9.8) |
9 F 33 M |
0 | 0 | 3 (3–8.5) | NA | 30, 71% | Mean 5.4 ± 2.6 years | 2.5 (1–6) |
Cobo-Calvo et al. [14] | 56 including MS |
Median 39.9 (32.3–58.1) |
30 F 16 M |
0 | 13 | 5.0 (3.5–7.8) | 19/56, 33.9% | 16, 28.6% | Median 42.2 months (25–79.5) | 2.5 (1.5–4.8) |
This cohort | 53 | Median 38 (16–80) |
28 F 25 M |
0 | 0 | 6 (1–8.5) | 29/53, 55% | 12/53, 24.5% | Median 3.94 years (1.5–12) mean 4.47 years | 4 (0–8) |
Ab antibody, EDSS Expanded Disability Status Scale, F female, M male, MS multiple sclerosis, ADEM acute disseminated encephalomyelitis